100 related articles for article (PubMed ID: 24251901)
1. The effect of varenicline on the development and expression of nicotine-induced behavioral sensitization and cross-sensitization in rats.
Goutier W; Kloeze MB; McCreary AC
Addict Biol; 2015 Mar; 20(2):248-58. PubMed ID: 24251901
[TBL] [Abstract][Full Text] [Related]
2. Varenicline and mecamylamine attenuate locomotor sensitization and cross-sensitization induced by nicotine and morphine in mice.
Biala G; Staniak N
Pharmacol Biochem Behav; 2010 Aug; 96(2):141-7. PubMed ID: 20451547
[TBL] [Abstract][Full Text] [Related]
3. A comparison of brain and behavioral effects of varenicline and nicotine in rats.
King J; Huang W; Chen W; Heffernan M; Shields J; Rane P; Bircher R; DiFranza JR
Behav Brain Res; 2011 Sep; 223(1):42-7. PubMed ID: 21527291
[TBL] [Abstract][Full Text] [Related]
4. Effect of varenicline on the acute and repeated locomotor responses to nicotine in rats.
Zaniewska M; McCreary AC; Stefański R; Przegaliński E; Filip M
Synapse; 2008 Dec; 62(12):935-9. PubMed ID: 18798299
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.
Rollema H; Chambers LK; Coe JW; Glowa J; Hurst RS; Lebel LA; Lu Y; Mansbach RS; Mather RJ; Rovetti CC; Sands SB; Schaeffer E; Schulz DW; Tingley FD; Williams KE
Neuropharmacology; 2007 Mar; 52(3):985-94. PubMed ID: 17157884
[TBL] [Abstract][Full Text] [Related]
6. The effect of nicotine induced behavioral sensitization on dopamine D1 receptor pharmacology: An in vivo and ex vivo study in the rat.
Goutier W; O'Connor JJ; Lowry JP; McCreary AC
Eur Neuropsychopharmacol; 2015 Jun; 25(6):933-43. PubMed ID: 25795518
[TBL] [Abstract][Full Text] [Related]
7. Divergent functional effects of sazetidine-a and varenicline during nicotine withdrawal.
Turner JR; Wilkinson DS; Poole RL; Gould TJ; Carlson GC; Blendy JA
Neuropsychopharmacology; 2013 Sep; 38(10):2035-47. PubMed ID: 23624742
[TBL] [Abstract][Full Text] [Related]
8. Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of alpha4beta2 nicotinic receptors in rats.
Spiller K; Xi ZX; Li X; Ashby CR; Callahan PM; Tehim A; Gardner EL
Neuropharmacology; 2009 Jul; 57(1):60-6. PubMed ID: 19393252
[TBL] [Abstract][Full Text] [Related]
9. Varenicline disrupts prepulse inhibition only in high-inhibitory rats.
Goktalay T; Buyukuysal S; Uslu G; Coskun AS; Yorgancioglu A; Kayir H; Uzbay T; Goktalay G
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Aug; 53():54-60. PubMed ID: 24632394
[TBL] [Abstract][Full Text] [Related]
10. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking.
Steensland P; Simms JA; Holgate J; Richards JK; Bartlett SE
Proc Natl Acad Sci U S A; 2007 Jul; 104(30):12518-23. PubMed ID: 17626178
[TBL] [Abstract][Full Text] [Related]
11. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.
Coe JW; Brooks PR; Vetelino MG; Wirtz MC; Arnold EP; Huang J; Sands SB; Davis TI; Lebel LA; Fox CB; Shrikhande A; Heym JH; Schaeffer E; Rollema H; Lu Y; Mansbach RS; Chambers LK; Rovetti CC; Schulz DW; Tingley FD; O'Neill BT
J Med Chem; 2005 May; 48(10):3474-7. PubMed ID: 15887955
[TBL] [Abstract][Full Text] [Related]
12. Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers.
Loughead J; Ray R; Wileyto EP; Ruparel K; Sanborn P; Siegel S; Gur RC; Lerman C
Biol Psychiatry; 2010 Apr; 67(8):715-21. PubMed ID: 20207347
[TBL] [Abstract][Full Text] [Related]
13. The alpha4beta2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats.
O'Connor EC; Parker D; Rollema H; Mead AN
Psychopharmacology (Berl); 2010 Feb; 208(3):365-76. PubMed ID: 19967529
[TBL] [Abstract][Full Text] [Related]
14. The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system.
Ericson M; Löf E; Stomberg R; Söderpalm B
J Pharmacol Exp Ther; 2009 Apr; 329(1):225-30. PubMed ID: 19126781
[TBL] [Abstract][Full Text] [Related]
15. Neuronal nicotinic receptor agonists improve gait and balance in olivocerebellar ataxia.
Wecker L; Engberg ME; Philpot RM; Lambert CS; Kang CW; Antilla JC; Bickford PC; Hudson CE; Zesiewicz TA; Rowell PP
Neuropharmacology; 2013 Oct; 73():75-86. PubMed ID: 23711550
[TBL] [Abstract][Full Text] [Related]
16. Nicotine-induced locomotor sensitization: pharmacological analyses with candidate smoking cessation aids.
Goutier W; Kloeze M; McCreary AC
Addict Biol; 2016 Mar; 21(2):234-41. PubMed ID: 25307867
[TBL] [Abstract][Full Text] [Related]
17. Varenicline improves mood and cognition during smoking abstinence.
Patterson F; Jepson C; Strasser AA; Loughead J; Perkins KA; Gur RC; Frey JM; Siegel S; Lerman C
Biol Psychiatry; 2009 Jan; 65(2):144-9. PubMed ID: 18842256
[TBL] [Abstract][Full Text] [Related]
18. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors.
Mihalak KB; Carroll FI; Luetje CW
Mol Pharmacol; 2006 Sep; 70(3):801-5. PubMed ID: 16766716
[TBL] [Abstract][Full Text] [Related]
19. Effects of the nicotinic receptor partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats.
LeSage MG; Shelley D; Ross JT; Carroll FI; Corrigall WA
Pharmacol Biochem Behav; 2009 Jan; 91(3):461-7. PubMed ID: 18817808
[TBL] [Abstract][Full Text] [Related]
20. The high-affinity nAChR partial agonists varenicline and sazetidine-A exhibit reinforcing properties in rats.
Paterson NE; Min W; Hackett A; Lowe D; Hanania T; Caldarone B; Ghavami A
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1455-64. PubMed ID: 20708056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
